
Sodium glucose co‐transporter‐2 inhibitors (SGLT‐2i) improve cardiorenal outcomes in patients with chronic kidney disease (CKD), with and without type 2 diabetes. The molecular mechanisms underlying these pleiotropic effects remain unclear, yet it is speculated that SGLT‐2i elicit a neurohormonal modulation resulting in renin‐angiotensin system (RAS) activation. We hypothesized that combined SGLT‐2 and angiotensin‐converting enzyme inhibition (ACEi) favours RAS regulation towards the beneficial angiotensin‐(1‐7)‐driven axis. This randomized controlled prospective study investigated the effect of 12 weeks treatment with the SGLT‐2i empagliflozin on top of ACEi on the molecular RAS dynamics in 24 diabetic and 24 non‐diabetic patients with CKD...
Like
Save
Share